Moderna, Inc. (NASDAQ:MRNA) Insider Juan Andres Sells 5,000 Shares


Share on StockTwits

Moderna, Inc. (NASDAQ:MRNA) insider Juan Andres sold 5,000 shares of the company’s stock in a transaction on Monday, May 3rd. The stock was sold at an average price of $183.66, for a total value of $918,300.00.

Juan Andres also recently made the following trade(s):

  • On Wednesday, April 28th, Juan Andres sold 5,000 shares of Moderna stock. The stock was sold at an average price of $182.32, for a total value of $911,600.00.
  • On Monday, April 26th, Juan Andres sold 5,000 shares of Moderna stock. The shares were sold at an average price of $171.77, for a total value of $858,850.00.
  • On Wednesday, April 21st, Juan Andres sold 5,000 shares of Moderna stock. The stock was sold at an average price of $158.60, for a total value of $793,000.00.
  • On Monday, April 19th, Juan Andres sold 5,000 shares of Moderna stock. The stock was sold at an average price of $166.17, for a total value of $830,850.00.
  • On Wednesday, April 14th, Juan Andres sold 5,000 shares of Moderna stock. The stock was sold at an average price of $153.75, for a total transaction of $768,750.00.
  • On Wednesday, April 7th, Juan Andres sold 5,000 shares of Moderna stock. The shares were sold at an average price of $131.63, for a total transaction of $658,150.00.
  • On Wednesday, March 31st, Juan Andres sold 5,000 shares of Moderna stock. The stock was sold at an average price of $121.10, for a total transaction of $605,500.00.
  • On Monday, March 29th, Juan Andres sold 5,000 shares of Moderna stock. The shares were sold at an average price of $130.05, for a total value of $650,250.00.
  • On Wednesday, March 17th, Juan Andres sold 5,000 shares of Moderna stock. The stock was sold at an average price of $149.78, for a total value of $748,900.00.
  • On Wednesday, March 10th, Juan Andres sold 5,000 shares of Moderna stock. The shares were sold at an average price of $133.24, for a total value of $666,200.00.

Shares of MRNA traded down $12.43 during mid-day trading on Tuesday, hitting $173.59. 16,846,072 shares of the company were exchanged, compared to its average volume of 11,744,357. The stock has a market cap of $69.53 billion, a price-to-earnings ratio of -107.15, a price-to-earnings-growth ratio of 0.53 and a beta of 1.73. Moderna, Inc. has a 1-year low of $46.13 and a 1-year high of $189.26. The company has a 50 day moving average of $151.16 and a 200-day moving average of $132.68. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.43 and a current ratio of 2.43.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.44). The firm had revenue of $570.80 million for the quarter, compared to analyst estimates of $279.41 million. Moderna had a negative net margin of 242.73% and a negative return on equity of 28.11%. Moderna’s revenue was up 3948.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.37) EPS. Research analysts anticipate that Moderna, Inc. will post -1.5 earnings per share for the current fiscal year.

Several brokerages have recently issued reports on MRNA. SVB Leerink restated a “sell” rating on shares of Moderna in a research note on Sunday, April 18th. Barclays raised their price target on shares of Moderna from $169.00 to $178.00 in a research report on Friday, February 26th. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a report on Friday, April 16th. Bank of America reissued a “sell” rating and set a $140.00 target price on shares of Moderna in a report on Friday, February 26th. Finally, Jefferies Financial Group upped their price target on shares of Moderna from $150.00 to $180.00 in a report on Thursday, February 18th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the company’s stock. Moderna currently has a consensus rating of “Hold” and an average price target of $152.22.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Black Swift Group LLC acquired a new stake in Moderna during the 4th quarter worth $26,000. Catalyst Capital Advisors LLC purchased a new position in shares of Moderna in the fourth quarter worth about $29,000. Sterling Investment Advisors Ltd. boosted its position in Moderna by 380.0% during the first quarter. Sterling Investment Advisors Ltd. now owns 240 shares of the company’s stock worth $31,000 after acquiring an additional 190 shares during the last quarter. Clearview Wealth Advisors LLC purchased a new stake in Moderna during the 4th quarter valued at about $32,000. Finally, Jeppson Wealth Management LLC acquired a new stake in Moderna in the 3rd quarter valued at about $33,000. 51.21% of the stock is owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics.

Featured Story: What is the S&P/ASX 200 Index?

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.